Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing

Interventions

DRUG: Ocrelizumab

Sponsor

Genentech, Inc.